FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943460583> ?p ?o ?g. }

• W2943460583 abstract "Background: It is well known that the prognosis of non pCR TNBC patients was poor after anthracycline and taxan treatment. For such patients, capecitabine seems to be effective to reduce recurrence based on the HR 0.58 of the CREATE X trial (Masuda, N. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 376, 2147. 2017) . However, the target of capecitabine is still unclear for TNBC. We classified non pCR tumors as BRCAness and Sporadic using BRCAness test(MRC-Holland, Amsterdam, the Netherlands). The recurrence rate of the BRCAness group was about 70%. Carboplatine is expected to be effective against BRCAness tumors, as it is a DNA damaging agent. In this study BRCAness can be checked just before carboplatin treatment using surgical specimens. Then the efficacy of carboplatin will be directly known to make comparison between DFS in the carboplatin group and that of the observation group. Trial design: This is anopen label, randomized phase III study that will enroll TNBC with residual invasive cancer after surgery with preoperative chemotherapy including both anthracycrine and taxan. Patients are randomly assigned to either the carboplatin group or observation group. The patients in the carboplatin group are treated with carboplatin at AUC 6 and those in the observation group are observed at only 3 years. Eligibility criteria: 1) ER and PgR 2) Preoperative chemotherapy including both anthracycrine and taxan. 3) Residual invasive cancer on breast tumors or lymph node metastasis in surgical specimens. 4) 20-79 year old women. 5) No chemotherapy within 5 years. 6) Not bilateral breast cancer, without metastasis, no prior breast cancer. 7) No severe bone marrow suppression. Specific aims:Primary objective is DFS (Disease Free Survival). Secondary objectives are overall survival and safety. STATISTICAL METHODS: The 3 years recurrence rate of the observation group was estimated as 40% and hazard ratio at 0.58 based on the CREATE X trial. For both groups, 135 patients are necessary. This study is powered to approximately 80% to test the superiority of carboplatin group at a 2-sided α=0.05 using a stratified log-rank test. Activation Date:22ndMarch 2018. No patients had been enrolled till 3rd July. Citation Format: Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4:J-CAT trial) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-05-04." @default.
• W2943460583 created "2019-05-09" @default.
• W2943460583 creator A5007874609 @default.
• W2943460583 creator A5008577264 @default.
• W2943460583 creator A5010062225 @default.
• W2943460583 creator A5011681054 @default.
• W2943460583 creator A5014474209 @default.
• W2943460583 creator A5015062076 @default.
• W2943460583 creator A5018318539 @default.
• W2943460583 creator A5031944340 @default.
• W2943460583 creator A5035036689 @default.
• W2943460583 creator A5039094816 @default.
• W2943460583 creator A5041090425 @default.
• W2943460583 creator A5045309176 @default.
• W2943460583 creator A5045705332 @default.
• W2943460583 creator A5056655144 @default.
• W2943460583 creator A5067561532 @default.
• W2943460583 creator A5067950730 @default.
• W2943460583 creator A5071189878 @default.
• W2943460583 creator A5072185320 @default.
• W2943460583 creator A5078301182 @default.
• W2943460583 creator A5084823182 @default.
• W2943460583 date "2019-02-15" @default.
• W2943460583 modified "2023-10-14" @default.
• W2943460583 title "Abstract OT1-05-04: Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4:J-CAT trial)" @default.
• W2943460583 doi "https://doi.org/10.1158/1538-7445.sabcs18-ot1-05-04" @default.
• W2943460583 hasPublicationYear "2019" @default.
• W2943460583 type Work @default.
• W2943460583 sameAs 2943460583 @default.
• W2943460583 citedByCount "0" @default.
• W2943460583 crossrefType "proceedings-article" @default.
• W2943460583 hasAuthorship W2943460583A5007874609 @default.
• W2943460583 hasAuthorship W2943460583A5008577264 @default.
• W2943460583 hasAuthorship W2943460583A5010062225 @default.
• W2943460583 hasAuthorship W2943460583A5011681054 @default.
• W2943460583 hasAuthorship W2943460583A5014474209 @default.
• W2943460583 hasAuthorship W2943460583A5015062076 @default.
• W2943460583 hasAuthorship W2943460583A5018318539 @default.
• W2943460583 hasAuthorship W2943460583A5031944340 @default.
• W2943460583 hasAuthorship W2943460583A5035036689 @default.
• W2943460583 hasAuthorship W2943460583A5039094816 @default.
• W2943460583 hasAuthorship W2943460583A5041090425 @default.
• W2943460583 hasAuthorship W2943460583A5045309176 @default.
• W2943460583 hasAuthorship W2943460583A5045705332 @default.
• W2943460583 hasAuthorship W2943460583A5056655144 @default.
• W2943460583 hasAuthorship W2943460583A5067561532 @default.
• W2943460583 hasAuthorship W2943460583A5067950730 @default.
• W2943460583 hasAuthorship W2943460583A5071189878 @default.
• W2943460583 hasAuthorship W2943460583A5072185320 @default.
• W2943460583 hasAuthorship W2943460583A5078301182 @default.
• W2943460583 hasAuthorship W2943460583A5084823182 @default.
• W2943460583 hasConcept C121608353 @default.
• W2943460583 hasConcept C126322002 @default.
• W2943460583 hasConcept C141071460 @default.
• W2943460583 hasConcept C143998085 @default.
• W2943460583 hasConcept C2776694085 @default.
• W2943460583 hasConcept C2777909004 @default.
• W2943460583 hasConcept C2778239845 @default.
• W2943460583 hasConcept C2780110267 @default.
• W2943460583 hasConcept C2781451048 @default.
• W2943460583 hasConcept C526805850 @default.
• W2943460583 hasConcept C530470458 @default.
• W2943460583 hasConcept C71924100 @default.
• W2943460583 hasConceptScore W2943460583C121608353 @default.
• W2943460583 hasConceptScore W2943460583C126322002 @default.
• W2943460583 hasConceptScore W2943460583C141071460 @default.
• W2943460583 hasConceptScore W2943460583C143998085 @default.
• W2943460583 hasConceptScore W2943460583C2776694085 @default.
• W2943460583 hasConceptScore W2943460583C2777909004 @default.
• W2943460583 hasConceptScore W2943460583C2778239845 @default.
• W2943460583 hasConceptScore W2943460583C2780110267 @default.
• W2943460583 hasConceptScore W2943460583C2781451048 @default.
• W2943460583 hasConceptScore W2943460583C526805850 @default.
• W2943460583 hasConceptScore W2943460583C530470458 @default.
• W2943460583 hasConceptScore W2943460583C71924100 @default.
• W2943460583 hasLocation W29434605831 @default.
• W2943460583 hasOpenAccess W2943460583 @default.
• W2943460583 hasPrimaryLocation W29434605831 @default.
• W2943460583 hasRelatedWork W1886389877 @default.
• W2943460583 hasRelatedWork W2002928668 @default.
• W2943460583 hasRelatedWork W2227329646 @default.
• W2943460583 hasRelatedWork W2331329572 @default.
• W2943460583 hasRelatedWork W2479591986 @default.
• W2943460583 hasRelatedWork W2534174115 @default.
• W2943460583 hasRelatedWork W2602012552 @default.
• W2943460583 hasRelatedWork W3021282540 @default.
• W2943460583 hasRelatedWork W3031200888 @default.
• W2943460583 hasRelatedWork W3172346887 @default.
• W2943460583 isParatext "false" @default.
• W2943460583 isRetracted "false" @default.
• W2943460583 magId "2943460583" @default.
• W2943460583 workType "article" @default.